Novel antipsychotic drugs on Progress of metabolic syndrome.doc

 PAGE \* MERGEFORMAT 12 Novel antipsychotic drugs on Progress of metabolic syndrome [Keywords:] new antipsychotic pathogenesis of metabolic syndrome Since the atypical antipsychotics such as clozapine (clozapine), olanzapine (alozapine), risperidone (risperi done), Quetiapine (quetiapine), Ali prazosin (aripiprazole), ziprasidone ( ziprasidone), and homes indole (sertindole) and so since the advent of these drugs on schizophrenia as positive, negative and affective symptoms were effective, less cognitive impairment, caused by a low risk of extrapyramidal side effects, its use has more than conventional antipsychotics, has been widely used to treat schizophrenia, schizophrenia relapse prevention, control manic episode with psychotic symptoms and other non-device quality or organic mental disorder. but the result of sugar lipid metabolism and other adverse reactions have been growing cause for concern. research shows that overall mortality in patients with schizophrenia is twice the general population, life expectancy shorter than 20% of the general population [1], the mortality rate increased in the early follow-up phase [2]. Another study showed that [3], schizophrenia population the incidence of type 2 diabetes in the general population is 3 to 4 times, it was reported incidence of diabetes in patients with schizophrenia nearly 10.8%, while diabetes in the general population is only about 3%, this new type of antipsychotic drugs and metabolic adverse effects are reviewed. 1 Metabolic syndrome and schizophrenia Reduced glucose tolerance, insulin resistance, diabetes, obesity (especially visceral obesity), lipid metabolism and hypertension are independent risk factors for cardiovascular disease, and often has, or within the same individual or the same family with a variety of metabolic related diseases closely linked, in view of the 1997 Zimmet and other advocates of these risk factors of metabolic endocrine disorder called metabolic syndrome (MS.